GlassScriptPhysician profile
Muna Q Khan
NPI 1801009949
$3,037.86
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $339 · 2021: $649 · 2022: $811 · 2023: $335 · 2024: $164 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $777.27 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Livanova USA, INC. | $508.62 | 2020-2022 | |
| Eisai INC. | $391.55 | 2019-2021 | |
| Sk Life Science, INC. | $255.46 | 2021-2025 | |
| Greenwich Biosciences, INC. | $163.43 | 2019-2021 | |
| Zogenix INC. | $145.95 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $135.35 | 2020-2022 | |
| Neurelis, INC. | $130.66 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $113.78 | 2023-2025 | Daybue |
| Sunovion Pharmaceuticals INC. | $90.69 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $64.21 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $61.94 | 2020-2022 | |
| Itf Therapeutics LLC | $32.09 | 2025 | |
| Abbvie INC. | $31.39 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $26.98 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $21.11 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $20.88 | 2024 | |
| Metacel Pharmaceuticals LLC | $19.42 | 2024 | Ozobax |
| Sumitomo Pharma America, INC. | $18.01 | 2024 | Aptiom |
| Molnlycke Health Care US, LLC | $15.89 | 2025 | Mepilex Border Ag, Melgisorb Plus, Mepilex Lite |
| Aucta Pharmaceuticals, INC. | $13.18 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muna Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.